Nasdaq pgen.
Dividend history information is presently unavailable for this company. This could indicate that the company has never provided a dividend or that a dividend is ...
Precigen (NASDAQ:PGEN) Insider Buying and Selling Activity. Current Insider Ownership Percentage 41.70%. Number Of Insiders Buying (Last 12 Months) 6. Amount Of Insider Buying (Last 12 Months) $21.01 M. Number Of Insiders Selling (Last 12 Months) 5. Amount Of Insider Selling (Last 12 Months) $513,769.48.Find the latest historical data for Precigen, Inc. Common Stock (PGEN) at Nasdaq.com.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...
Nov 20, 2023 · In the last trading session, 2.49 million Precigen Inc (NASDAQ:PGEN) shares changed hands as the company’s beta touched 1.83. With the company’s per share price at $1.18 changed hands at $0.03 or 2.61% during last session, the market valuation stood at $293.73M. PGEN’s last price was a discount, traded about -94.07% off its 52-week high ...
Precigen has generated $0.00 earnings per share over the last year. Earnings for Precigen are expected to grow in the coming year, from ($0.34) to ($0.28) per share. Precigen has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 4th, 2024 based off prior year's report dates.Back to PGEN Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen, Inc. Common Stock (PGEN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Feb 1, 2023 · The Trade: Precigen, Inc. (NASDAQ:PGEN) Director Randal J Kirk bought a total of 11,428,571 shares at an average price of $1.75. To acquire these shares, it cost around $20 million . Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent ...
Home - Precigen. Our disciplined design approach uses non-viral and viral expression systems, genome, DNA, RNA and protein engineering, and a suite of precision bioengineering switch technologies controlling gene expression and regulation to deliver potent on-target gene and cellular multifunctional therapies with improved safety and efficacy.
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...
GERMANTOWN, Md., May 10, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2023 financial results and business updates. "Precigen continues to execute on our strategy to maintain ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Insider trading information is an indicator that can be used to gain valuable insights and as a reflection of the prospect of the company.Dec 4, 2023 · InvestorPlace.com writer Gabriel Osorio-Mazzilli identifies Precigen (NASDAQ:PGEN) as a stock to buy this week following updates about the firm’s flagship PRGN-2012 therapy, an immunotherapy ... Nov 19, 2023 · Precigen (NASDAQ:PGEN – Get Free Report) and HUTCHMED (NASDAQ:HCM – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership. Institutional and Insider Ownership 22.5% of Precigen shares are held […]
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Sep 19, 2022 · You can click the graphic below for the historical numbers, but it shows that as of June 2022 Precigen had US$198.7m of debt, an increase on US$177.3m, over one year. On the flip side, it has US ... Jan 25, 2023 · Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ... Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent ...
Based on analysts offering 12 month price targets for PGEN in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .
GERMANTOWN, Md., Aug. 2, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2021 financial results after the market closes on Monday, …Jan 11, 2023 · Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ... Precigen (NASDAQ:PGEN – Get Free Report) and HUTCHMED (NASDAQ:HCM – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership. Institutional and Insider Ownership 22.5% of Precigen shares are held […]Nov 30, 2023 · The public float for PGEN is 128.23M, and currently, short sellers hold a 12.67% ratio of that floaft. The average trading volume of PGEN on November 30, 2023 was 1.32M shares. PGEN) stock’s latest price update. Precigen Inc (NASDAQ: PGEN) has experienced a rise in its stock price by 4.09 compared to its previous closing price of 1.10. Mar 6, 2023 · Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The average trading volume of PGEN on November 13, 2023 was 1.52M shares. PGEN) stock’s latest price update. The stock price of Precigen Inc (NASDAQ: PGEN) has plunged by -13.49 when compared to previous closing price of 1.26, but the company has seen a -9.92% decline in its stock price over the last five trading sessions.The gamut of surprising cannabis players is growing by the day, and now we can firmly add Intrexon (PGEN 1.75%) to the list. Image source: Getty Images. Intrexon really likes to think out of the boxSep 19, 2022 · You can click the graphic below for the historical numbers, but it shows that as of June 2022 Precigen had US$198.7m of debt, an increase on US$177.3m, over one year. On the flip side, it has US ...
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...
10 Jun, 2021, 16:05 ET. GERMANTOWN, Md ,, June 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell ...(NASDAQ: PGEN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.19%. What is PGEN's Price Target? According to 2 Wall Street analyst s that have issued a 1 year PGEN price target, the average PGEN price target is $10.00 , with the highest PGEN stock price forecast at $14.00 and the lowest PGEN stock ... NasdaqGS:PGEN Earnings and Revenue Growth June 29th 2021 We note that hedge funds don't have a meaningful investment in Precigen. Third Security, LLC is currently the largest shareholder, with 31% ...(NASDAQ: PGEN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.19%. What is PGEN's Price Target? According to 2 Wall Street analyst s that have issued a 1 year PGEN price target, the average PGEN price target is $10.00 , with the highest PGEN stock price forecast at $14.00 and the lowest PGEN stock ... Nasdaq Futures. 15511.25-27.25 (-0.18%). Dow Jones Futures. 34865.0074.00 (0.21 ... NASDAQ:PGEN · Buy Candidate. Precigen, Inc. Stock Price (Quote). NASDAQ Stock ...Precigen (NASDAQ: PGEN) $1.26 (-3.8%) -$0.05 Price as of November 8, 2023, 4:00 p.m. ET Key Data Points Current Price $1.26 Daily Change (-3.8%) -$0.05 Day's Range $1.21 - $1.31 Previous Close... Nov 30, 2023 · The latest price target for . Precigen (NASDAQ: PGEN) was reported by HC Wainwright & Co. on Thursday, August 10, 2023.The analyst firm set a price target for 6.00 expecting PGEN to rise to within ... I recently spoke with Oxitec CEO Hadyn Parry about the company's self-limiting insect platform, which was acquired by engineered biology conglomerate Intrexon ( PGEN -8.68%) in 2015. Aimed at ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...
Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies StocksFeb 1, 2023 · The Trade: Precigen, Inc. (NASDAQ:PGEN) Director Randal J Kirk bought a total of 11,428,571 shares at an average price of $1.75. To acquire these shares, it cost around $20 million . The Trade: Precigen, Inc. (NASDAQ:PGEN) Director Randal J Kirk bought a total of 11,428,571 shares at an average price of $1.75. To acquire these shares, it cost around $20 million .Instagram:https://instagram. best gold sellersotcmkts nhiqinvesting in insurance companiestd bank atm maximum withdrawal (NASDAQ: EXFY) filed a lawsuit in the U.S. District Court for the District of Oregon over alleged violations of Federal Securities Laws by… 01/22/2024. Veradigm ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. … best stock trading learning applvlv stock Precigen, Inc. Common Stock (PGEN) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. monthly etf Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent ...PRECIGEN, INC. (PGEN) SPO - NASDAQ.com.